FPR2 and gastric cancer: FPR2 induces epithelial mesenchymal transformation (EMT) by activating the mitogen-activated protein kinase (MAPK)/ERK pathway, thereby enhancing the invasive and metastatic ability of GC cells (Hou et al., 2017).